logoAiPathly

Atropos Health

A

Overview

Atropos Health is a pioneering company in healthcare and life sciences, specializing in translating real-world clinical data into personalized real-world evidence (RWE) to improve clinical outcomes, accelerate research, and enhance operational efficiency. Key Features and Technologies:

  1. GENEVA OS™: A Generative Evidence Acceleration Operating System that securely installs on medical data, structuring it for use by clinicians, researchers, and data scientists. It enables rapid generation of high-quality, publication-grade real-world evidence.
  2. Atropos Evidence™ Network: Provides access to de-identified records of approximately 200 million global patients, allowing organizations to run queries and generate evidence quickly. It includes the Alexandria™ library, containing over 10,000 past studies across more than 40 clinical specialties.
  3. ChatRWD™ and Green Button™ Informatics Consult Service: Tools that allow users to ask clinical questions and receive evidence-based answers in minutes, facilitated by a chat-based AI co-pilot and supported by medical experts. Mission and Impact: Atropos Health aims to address the "evidence gap" in healthcare, particularly for patients with multiple comorbidities or from understudied groups. By democratizing access to high-quality RWE, the company seeks to personalize clinical decisions, optimize care protocols, and conduct population health studies more effectively. Applications and Benefits:
  4. Precision Medicine: Enhances precision medicine programs by providing personalized insights for diagnosis, treatment selection, and care management.
  5. Clinical Decision-Making: Accelerates appropriate clinical decision-making, driving high-value, low-cost care tailored to individual patient physiology.
  6. Research and Development: Expedites research by generating novel retrospective observational studies in response to clinical questions, reducing time from months to minutes.
  7. Cost Savings and Efficiency: Helps health systems reduce healthcare costs through optimized care protocols, lower research costs, and improved patient outcomes. Partnerships and Funding: Atropos Health has received significant funding, including a $33 million Series B round led by Valtruis. The company has strategic partnerships with health systems like Mayo Clinic, and life sciences companies such as Janssen and Novartis. Founding and Leadership: Founded in 2019 by Brigham Hyde, Ph.D., Nigam Shah, MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D., who are leaders in AI and real-world evidence research in healthcare. The company is headquartered in Palo Alto, CA, and has a strong advisory board of healthcare leaders.

Leadership Team

Atropos Health's leadership team comprises experienced professionals with diverse backgrounds in medicine, finance, and corporate development. Founders and Executive Leadership:

  1. Brigham Hyde, PhD: Co-Founder and Chief Executive Officer
  2. Saurabh Gombar, MD PhD: Co-Founder and Chief Medical Officer
  3. Nigam Shah, PhD MBBS: Co-Founder and Chief Data Scientist at Stanford Health Care Key Executives:
  4. Neil Sanghavi: President, Products & Solutions
  5. Sharath Reddy: Chief Financial Officer and Head of Corporate Development
  6. Vladimir Polony: Director of Engineering
  7. Yen Low, PhD: Director of Real-World Data & Data Science
  8. Cecily Harris: Legal
  9. Kris Karson: Corporate Development
  10. Rehan Chawdry: Engineering
  11. Joy Somogyi: Marketing
  12. Annie Daskovsky: Finance
  13. Kevin Smith: Health System Sales
  14. Chris Lento: Life Science Sales Advisory Boards: Atropos Health has both a Clinical Advisory Board and a Life Sciences Advisory Board, comprising healthcare industry leaders who advise on the company's strategies and innovations. Clinical Advisory Board Key Members:
  15. Nick Patel, MD: Chair of the Advisory Board
  16. Neera Ahuja, MD: Division Chief – Hospital Medicine at Stanford University School of Medicine
  17. Robert Harrington, MD: Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University
  18. Rasu Shrestha, MD, MBA: Chief Innovation and Commercialization Officer at Advocate Health Life Sciences Advisory Board Key Members:
  19. Barbara Salami: Former Vice President at Moderna
  20. Dr. Gabriel Eichler: Founder and Managing Director of Oak Health Partners This diverse leadership team brings a wealth of experience in healthcare, technology, and business, positioning Atropos Health at the forefront of AI-driven healthcare solutions.

History

Founding and Early Development:

  • Founded in 2019 as a spin-out of Stanford University's "Green Button" technology
  • Originated from a research project led by co-founders Brigham Hyde, Nigam Shah, and Saurabh Gombar
  • Aimed to leverage anonymized electronic medical records (EMRs) to inform patient care Key Milestones:
  1. Seed Funding and Initial Deployment (December 2020):
    • Announced launch and completion of seed funding round
    • Supported by Boston Millennia Founders Fund and others
    • Selected as a participant in StartX 2020
    • Deployed service within Stanford Health Care for two years
  2. Series A Funding (August 2022):
    • Raised $14 million led by Breyer Capital
    • Expanded commercial team and developed oncology product
    • Appointed Brigham Hyde as CEO
  3. Series B Funding (May 2024):
    • Secured $33 million to scale AI-powered real-world evidence platform
    • Focused on life sciences partnerships and international expansion Technological Advancements:
  4. Geneva OS (Fall 2023):
    • Includes ChatRWD chatbot interface
    • Reduces time to produce high-quality real-world evidence
  5. Atropos Evidence Platform:
    • Uses search technology licensed from Stanford University
    • Generated over 50 peer-reviewed studies
  6. Atropos Evidence Network:
    • Federal data network based on healthcare institution partners
    • Access to over 200 million unique de-identified patient records Significant Partnerships:
  • Janssen Research & Development
  • Cencora
  • Arcadia
  • xCures
  • Strategic funding from Presidio Ventures, Samsung Next, Gaingels, and Audere Capital Mission and Impact:
  • Aims to fill the evidence gap in healthcare
  • Provides personalized real-world data-driven evidence to caregivers
  • Improves patient outcomes and reduces healthcare expenditures
  • Saved clients over $100 million through expedited analytics and cost-saving measures Atropos Health's history reflects rapid growth and innovation in the field of AI-driven healthcare solutions, positioning the company as a leader in real-world evidence generation and application.

Products & Solutions

Atropos Health offers innovative solutions leveraging real-world data (RWD) to support clinical decision-making, research, and operational efficiency in healthcare and life sciences:

  1. Evidence Generation Solutions: Translates real-world clinical data into personalized real-world evidence (RWE) to close evidence gaps.
  2. GENEVA OS™: The Generative Evidence Acceleration Operating System securely installs on medical data, structuring it for use by clinicians, researchers, and data scientists. Users can ask clinical questions via ChatRWD™ or the Green Button™ Informatics Consult Service.
  3. Atropos Evidence™ Network and Alexandria™: Provides access to de-identified records of approximately 200 million global patients and a library of over 10,000 past studies across 40+ clinical specialties.
  4. Advanced Cohort Engine (ACE): Developed in collaboration with Stanford clinicians, ACE searches longitudinal patient records using Temporal Query Language (TQL).
  5. Real-Time Analytics and Comparative Effectiveness Research: Enables organizations to monitor interventions in real-time and optimize clinical operations, care pathways, and drug formularies.
  6. Clinical Decision Support: Accelerates appropriate clinical decision-making, supported by medical doctors, epidemiologists, statisticians, and other experts.
  7. Integration and Security: HIPAA-compliant and integrates with various health systems, allowing quick deployment and immediate access to the Atropos Evidence™ Network.
  8. Pricing and Accessibility: Available on platforms like AWS Marketplace, with pricing starting from $1.00/hr or $100.00/yr, plus AWS usage fees. Atropos Health's solutions aim to transform healthcare by providing rapid, methodologically credible real-world evidence, supporting better clinical decisions, research, and operational efficiency.

Core Technology

Atropos Health's core technology revolves around several key components that facilitate the use of real-world data (RWD) and artificial intelligence (AI) in healthcare:

  1. GENEVA OS™: The Generative Evidence Acceleration Operating System is designed for rapid healthcare evidence generation across a robust network of real-world data. It automates and standardizes evidence and insight generation for healthcare and life science institutions.
  2. Atropos Evidence™ Network: A federated healthcare data network providing access to over 300 million patient records. This network enables training, testing, and deployment of AI models using high-quality, de-identified real-world data, benefiting AI developers, health systems, life sciences organizations, and data holders.
  3. ChatRWD™: An AI co-pilot integrated with GENEVA OS™, using an LLM-independent framework to maintain security and integrity. It significantly reduces the time required to produce high-quality, publication-grade real-world evidence from months to minutes.
  4. Real-World Data (RWD) and Real-World Evidence (RWE): The platform leverages RWD to generate RWE, crucial for improving patient care and outcomes. This approach ensures AI models output accurate recommendations for researchers and clinicians, supporting precision medicine initiatives.
  5. Automation and Transparency: Built on principles of quality, transparency, and automation, Atropos Health prioritizes patient safety and responsible AI use. The technology ensures AI models are developed and deployed with emerging assurance standards on AI transparency and bias detection. Atropos Health's core technology combines these elements to provide a comprehensive platform for generating and utilizing real-world evidence in healthcare, supporting rapid clinical decision-making, research, and operational efficiency.

Industry Peers

Atropos Health operates within the digital health and healthcare analytics sector. Here are some of its key industry peers and competitors:

  1. Komodo Health: Specializes in healthcare analytics, providing insights from a range of healthcare data to improve patient care and reduce disease burden.
  2. Holmusk: Focuses on behavioral health, offering a real-world evidence platform leveraging AI-powered analytics and digital solutions.
  3. Evidation: Harnesses real-world health data to measure and improve health outcomes, serving life sciences companies, government bodies, and academic institutions.
  4. Tempus: Known for advanced genomic and transcriptomic analysis, providing personalized cancer treatment options and real-world evidence generation.
  5. Paradigm: While not exclusively focused on healthcare analytics, it competes with Atropos Health in terms of overall market presence and revenue scale.
  6. Datavant: Specializes in linking health data to improve patient outcomes, often mentioned alongside Atropos Health in industry analyses. Key Differentiators: Atropos Health stands out with its Evidence Network, allowing users to query a vast network of patient data (over 300 million patients) without data sales, ensuring HIPAA compliance and data security. It utilizes generative AI to produce real-world evidence reports quickly and at scale. Similarities: These companies share a focus on leveraging large datasets and advanced analytics to improve healthcare outcomes, optimize health systems, and accelerate clinical research. However, each has a unique approach and area of specialization within the broader healthcare technology landscape. Atropos Health's combination of a vast patient data network, generative AI capabilities, and focus on rapid, scalable evidence generation positions it uniquely in the competitive landscape of healthcare analytics and real-world evidence platforms.

More Companies

C

CYNGN

C

Citi

Citigroup Inc., commonly known as Citi, is a multinational investment bank and financial services company headquartered in New York City. With a rich history dating back to 1812, Citi has evolved into one of the world's leading financial institutions. ## History and Formation Founded as the City Bank of New York in 1812, Citi has grown through numerous mergers and innovations. A significant milestone was the 1998 merger of Citicorp and Travelers Group, forming Citigroup. However, Travelers was spun off in 2002. ## Structure and Operations Citi operates through two major divisions: 1. Institutional Clients Group (ICG): Offers investment banking, corporate banking, treasury and trade solutions, and securities services. 2. Personal Banking and Wealth Management (PBWM): Includes retail banking, credit card services, and wealth management. The company provides a wide range of financial services, including: - Retail, commercial, and investment banking - Securities brokerage - Trade and securities services - Wealth management solutions - Accounts and deposit services - Loans and mortgages - Small business banking solutions - Corporate and institutional services ## Global Presence Citi maintains a significant global footprint, serving clients in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Its diverse client base includes individuals, corporations, small businesses, and institutional and government entities. ## Key Initiatives and Innovations - Pioneered the world's first ATM and introduced 24-hour PC banking in the UK - Implemented Smart Banking branches and 24-hour service units globally - Launched innovative credit card products and expanded retail banking operations - Committed to diversity and inclusion (D&I) and environmental, social, and governance (ESG) initiatives ## Leadership Jane Fraser became CEO in February 2021, making history as the first woman to lead a major Wall Street firm. Under her leadership, Citi has intensified its focus on addressing social issues, including the U.S. racial wealth gap through its Action for Racial Equity initiative. ## Financial Status As one of the Big Four banking institutions in the United States, Citi is considered a systemically important bank by the Financial Stability Board. It consistently ranks among the top global investment banks and maintains a strong position in various financial rankings: - #24 in the Forbes Global 2000 (2023) - 36th on the Fortune 500 (2023) Citi's continued evolution and adaptation to the changing financial landscape solidify its position as a key player in the global banking industry.

A

Aviceda Therapeutics

Aviceda Therapeutics is a private, clinical-stage biotechnology company based in Cambridge, Massachusetts. The company specializes in developing next-generation immunomodulators to address various diseases, with a particular focus on those involving the innate immune system and chronic, non-resolving inflammation. ### Key Focus Areas - **Glyco-Immune Therapeutics**: Aviceda s proprietary Glyco-Code technology platform and High Affinity Ligands of Siglecs (HALOS™) nanotechnology are leveraged to modulate the innate immune response. This innovative approach targets glyco-immune checkpoints and exploits interactions between glycans and innate immune cells. ### Therapeutic Pipeline 1. **Ophthalmology**: - AVD-104: An intravitreal glycomimetic nanoparticle for geographic atrophy (GA) secondary to age-related macular degeneration. Currently in Phase 2b/3 clinical trials. - AVD-302: In development for diabetic retinopathy. - AVD-401: Targeting retinoblastoma. 2. **Other Indications**: - AVD-601: Oncology - AVD-701: Neurology - AVD-801 and AVD-901: Fibrosis ### Technology and Platforms 1. **Cell-Based High-Throughput Screening (HTS)**: Enables rapid screening, selection, and optimization of ligands with high affinity and specificity for innate immune cells. 2. **Nanoparticle Technology**: Proprietary delivery system for therapeutics, exemplified by the glycan-coated nanoparticles in AVD-104. ### Funding and Development Aviceda recently secured $207.5 million in Series C financing to advance its lead program, AVD-104, into pivotal trials. This substantial funding was backed by prominent healthcare funds and investors, demonstrating strong confidence in the company s potential. ### Leadership and Expertise The company boasts a cross-disciplinary team of recognized scientists, clinicians, and drug developers. Following the Series C financing round, Aviceda expanded its board of directors with industry experts, further strengthening its leadership position. In conclusion, Aviceda Therapeutics is well-positioned to address a wide range of inflammatory, degenerative, and fibrotic diseases through its innovative glyco-immune therapeutics and advanced technology platforms. The company s robust pipeline, cutting-edge technology, and strong financial backing make it a notable player in the biotechnology industry.

F

Form Energy